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cirst report of an OXA-58 carbapenemase-
roducing Acinetobacter baumannii isolated from
rinary tract infection, in Morocco
cinetobacter  baumannii  are organisms frequently found in the
nvironment. This bacterium causes several types of infections,
uch as bacteremia, pneumonia and urinary tract infection [1].
arbapenem resistance in A.  baumannii  is more often caused
y the production of OXA-type carbapenemases and metallo--
actamases. The OXA-type carbapenemases are divided into four
ub-groups: blaOXA-23, blaOXA-40, blaOXA-51 and blaOXA-58 [2].
n 80-year-old diabetic man was admitted to the Department of
edicine at the referral Hospital Hassan II in Settat city, Morocco.
he patient presented a symptom of acute gastroenteritis and was
ospitalized between the 1st and 21st November 2014. He had
reviously required surgical intervention for intestinal obstruction
yndrome in the surgery ward in July 2014. Since then, our patient
resented chronic diarrhoea with fever (39 ◦C), along with vomiting
nd a general physical health deterioration, as well as pancytopenia
nd an oral candidiasis. The hospitalized patient was initially treated
ith oral ciprofloxacin 500 mg, twice per day for 10 days (D1 to
10), then he was treated with oral amoxicillin/clavulanic acid 1 g,
wice per day for 10 days (D11 to D20) along with metronidazole
00 mg, three times per day for 10 days (D12 to D21); flucona-
ole (50 mg/day) was added for the oral candidiasis. The patient’s
linical state was improved. On the last day of the patient’s hospital-
zation, a urinary tract infection was suspected because the patient
elt a burning on urination. A cytobacteriological examination of
rine was positive for A.  baumannii. This bacterium was isolated
rom one site (urine). Unfortunately, the patient insisted on leaving
ospital against his doctor’s advice, and interrupted treatment and
ospitalization, so we have been unable to search other infection
ites caused by this isolate.
.  baumannii  isolate was identified using standard microbiological
ethods [3], while the antibiotic susceptibility profile was deter-
ined by using the standard diffusion disc method. The modified
odge test and the ethylene-diamine-tetra-acetic (EDTA) disc syn-
rgy test were performed for the screening of carbapenemases and
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atory Standards Institute recommendations [4].
his isolate was resistant to piperacilline-tazobactam, cefotaxime,
eftazidime, ciprofloxacin, and imipenem. The antimicrobial drugs
ffective against the isolate were colistin, gentamicin and amikacin.
he A.  baumannii  isolate was positive for modified Hodge test and
creened by conventional single-plex PCR assay for the follow-
ng carbapenemase genes: blaVIM, blaIMP, blaGES, blaKPC, blaOXA-58,
laOXA-40, blaOXA-23, blaOXA-24 and blaOXA-51 [5]. The polymerase
hain reaction and sequencing analysis revealed the presence of
laOXA-58 gene. We noted that the A.  baumannii  isolate was detected
n the same department in August 2014. In our case, the risk fac-
ors responsible for developing such infections were: increasing
ge, length of hospital stay, previous hospitalization, diabetes mel-
itus and admission to surgical wards. These risk factors have been
eported in previous studies [6].
ince the renal function of the patient was normal and only col-
stin and amino-glycosides (amikacin and gentamicin) are effective
gainst infection with drug-resistant A.  baumannii, a colistin and
entamycin or colistin and amikacin combination could have been
ested if our patient had not left the hospital against medical advice.
mino-glycoside agents are generally used in combination therapies
ith another active antimicrobial agent [7,8].
n this report, we describe the first identification of an A.  baumannii
linical isolate harbouring the blaOXA-58 gene in Settat city, Morocco.
he strain of A.  baumannii  carrying OXA-58 carbapenemase was
nitially described in France in the outbreak of a hospital infection
n 2003, and since then it has been found around the world (Italy,
elgium, Greece, Iran, Turkey) [9].
hese bacteria can survive for long periods in the hospital envi-
onment, which signifies that the hospital environment serves as a
eservoir for multidrug-resistant strains to persist during epidemics.
herefore it is essential to apply strict infection control measures
oupled with careful environmental disinfections [10].
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